Bortezomib affects TRAIL signaling at multiple levels including enhancement of TRAIL-induced caspase 8 cleavage and activation, inhibition of the cell cycle, changes in cell adherence, inhibition of NF-κB activation and overcomes TRAIL resistance in various tumor cells [18]. The gene discussed is TNFSF10; the disease is neoplasm.